Transdermal system with fentanyl
AssigneeHexal AG
InventorsKatalin Tisa-Bostedt, Wilfried Fischer, Christian Leichs
Life of this patent
Estimating the term…
Abstract
This invention relates to a transdermal system containing fentanyl as the active ingredient and consisting of or comprising a substrate, a mixture of the following ingredients applied to the substrate: the active ingredient, an oil-based aloe vera extract, a resin, and an adhesive, as well as a layer laminated to the mixture applied to the substrate.
Claims15
A transdermal system containing fentanyl as the active ingredient and consisting of
- a substrate,
- a mixture of the following ingredients applied to the substrate,
- the active ingredient,
- an oil-based aloe vera extract,
- a resin, and
- an adhesive, as well as
- a layer laminated to the mixture applied to the substrate.
The transdermal system according to one of the preceding claims, characterize by an aloe vera extract containing approximately 7% oil of aloe leaves and approximately 93% soy oil (based on weight).
The transdermal system according to one of the preceding claims, characterized by an ester of colophony, a hydrogenated colophony ester, a synthetic organic resin and/or a synthetic hydrocarbon compound as the resin.
The transdermal system according to one of the preceding claims, characterized by a ratio of aloe vera extract to resin in the range of 0.1:1 to 99:1, preferably 0.2:1 to 50:1 and in particular 0.5:1 to 15:1 (based on weight).
The transdermal system according to one of the preceding claims, characterized by a thermoplastic elastomer, in particular a pressure-sensitive thermoplastic elastomer as the adhesive, in particular a thermoplastic elastomer based on a block copolymer, preferably a styrene-butadiene-styrene block copolymer (SBS), a styrene-isoprene-styrene block copolymer (SIS) or a styrene-ethylene/butadiene -styrene block copolymer (SE/BS) or a hydrocarbon adhesive, preferably an acrylate adhesive or a polyisobutylene adhesive or a silicone adhesive.
The transdermal system according to one of the preceding claims, characterized in that the transdermal system does not have any additional fixative aid except for the components according to one of the preceding claims.
The transdermal system according to one of the preceding claims, characterized by a fentanyl-to-adhesive ratio in the range of 0.1:1 to 1:1, and preferably 0.1:1 (based on weight).
The transdermal system according to one of the preceding claims, characterized by a removable protective layer, preferably a siliconized plastic film, in particular a siliconized polyester film, a fluorinated plastic film or siliconized paper as the substrate.
The transdermal system according to one of the preceding claims, characterized by a plastic film, in particular a polyester film, a nonwoven web, a plastic foam or a fabric as the laminating layer.
The transdermal system according to one of the preceding claims, characterized in that the laminating film is designed as a covering layer, which is impermeable for the active ingredient.
The transdermal system according to one of the preceding claims, characterized by a ratio of the weight per unit of area of the matrix in the range of 20 to 200 g/m2, preferably 50 to 120 g/m2.
The transdermal system according to one of the preceding claims, characterized by the fact that it contains a conventional filler, a skin-protective agent and/or tackifying agent.
The transdermal system according to one of the preceding claims, characterized in that the system is provided in a package or a bag.
Dependencies are inferred from the claim text.